Patient communities are key partners in communications for pharmaceutical companies. But what does an impactful partnership look like? The Patient Partnerships Index 2020 aims to establish this.
Now, more than ever, we’re in need of cooperation – a shared perspective on how we can do things differently. We need to bring together the two forces operating at scale right now to counter the effects of COVID-19.
First, there are the patient groups, tirelessly working to provide their communities with information, support and funds to safely get them through this difficult time. Second are the pharmaceutical companies working at pace to develop potential vaccines, seconding staff and lab facilities to the frontline effort to ensure the UK’s exit strategy has a meaningful impact on lives. At the same time, they are securing continuity of supply and getting medicines to where they need to be.
Putting patients at the heart of what the life science sector does has never been more critical. The Index will enable both pharmaceutical companies and patient groups to thrive, not just survive – so patients can ultimately live happier, healthier lives.Jenny Ousbey, MD, OVID Health
All of this inspirational activity could not provide a better impetus for the Patient Partnership Index. The Index is the culmination of thoughtful discussion and research, with a sole goal in mind: to improve patient outcomes through high quality patient-pharmaceutical partnerships in communications, advocacy and market access.
The concept of patient centricity is mainstream now in research and development, including in clinical trials and patient support programmes. But the Index looks beyond ‘centricity’ in R&D and into partnerships of equals for three reasons: one, because ‘centricity’ can be passive; two, it is traditionally tied to R&D; and three, because top quality communications between companies and patient groups is about collaborating as equals.